COMMUNIQUÉS West-GlobeNewswire

Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3
15/02/2024
Chiffre d’affaires de 17,5 millions d’euros pour l’année 2023, contre 12,2 millions d’euros sur la même période en 2022 Trésorerie et équivalents de trésorerie à 26,9 millions d’euros, dépôt à court-terme de 0,01 [...]
BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2023 Financial Results and Hold Investor Conference Call on February 29, 2024
15/02/2024
LOUISVILLE, Ky., Feb. 15, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its fourth quarter and full year 2023 [...]
Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
15/02/2024
Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024 Mont-Saint-Guibert, Belgium – February 15, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah [...]
Nyxoah Publiera ses Résultats Financiers du Quatrième Trimestre et de l'Exercice 2023 le 5 Mars 2024
15/02/2024
Nyxoah Publiera ses Résultats Financiers du Quatrième Trimestre et de l'Exercice 2023 le 5 Mars 2024 Mont-Saint-Guibert, Belgique – 15 février 2024, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH [...]
Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
15/02/2024
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
15/02/2024
Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of $20 [...]
CooperCompanies 4-for-1 Stock Split Effective Friday (2/16)
15/02/2024
SAN RAMON, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced that its four-for-one stock split will become effective on Friday, February 16, 2024, at 5:00 PM ET, and trading is [...]
AMN Healthcare Announces Fourth Quarter and Full Year 2023 Results
15/02/2024
Quarterly revenue of $818 million ; GAAP EPS of $0.33 and adjusted EPS of $1.32 DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for [...]
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15/02/2024
FARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies [...]
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
15/02/2024
MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, [...]
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
15/02/2024
Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid [...]
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
15/02/2024
CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
15/02/2024
SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal [...]
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
15/02/2024
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]
QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification
15/02/2024
Additional ecofriendly QIAwave kits for DNA and RNA extraction receive ACT Label due to greatly improved Environmental Impact Factor compared to standard kits // QIAGEN’s Sample technologies R&D lab in Germany [...]
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
15/02/2024
Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 WALTHAM, Mass., Feb. 15 [...]
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
15/02/2024
Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE [...]
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
15/02/2024
MOUNTAIN VIEW, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it [...]
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
15/02/2024
First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in [...]

Pages